title: Percutaneous transluminal angioplasty versus endovascular stent placement in the treatment of venous stenoses in patients undergoing hemodialysis: intermediate results.
abstract: OBJECTIVE
  This report describes intermediate findings from an ongoing prospective randomized trial comparing the results of percutaneous transluminal angioplasty (PTA) with results of endovascular stent placement in patients undergoing hemodialysis.
  
  
  METHODS
  Among 87 consecutive patients with venous stenoses or occlusions, 47 (54%) were treated with PTA alone and 40 (46%) were treated with PTA and stent placement.
  
  
  RESULTS
  For peripheral sites, the primary patency rates for PTA at 60, 180, and 360 days were 55%, 31%, and 10%, respectively, and for stents were 36%, 27%, and 11%, respectively (P = .6528). The secondary patency rates for PTA at 60, 180, and 360 days were 94%, 80%, and 71%, respectively, and for stents were 73%, 64%, and 64%, respectively (P = .1677). For central sites, the primary patency rates for PTA at 60, 180, and 360 days were 81%, 23%, and 12%, respectively, and for stents were 67%, 11%, and 11%, respectively (P = .4595). The secondary patency rates for PTA were 100% at each interval, and for stents were 100%, 89%, and 78%, respectively (P = .5408).
  
  
  CONCLUSIONS
  Intermediate results suggest that, overall, there is no difference in the patency rates for peripheral venous stenoses in dialysis patients treated with PTA or PTA and endovascular stent placement. At this time, the numbers of patients are too small to conclude if certain sites such as larger central veins will respond better to one treatment or the other.
authors.affiliation: Department of Radiology, Good Samaritan Hospital, Portland, OR 97210, USA.
authors.forename: S F
authors.initials: SF
authors.lastname: Quinn
authors.forename: E S
authors.initials: ES
authors.lastname: Schuman
authors.forename: T A
authors.initials: TA
authors.lastname: Demlow
authors.forename: B A
authors.initials: BA
authors.lastname: Standage
authors.forename: J W
authors.initials: JW
authors.lastname: Ragsdale
authors.forename: G S
authors.initials: GS
authors.lastname: Green
authors.forename: R C
authors.initials: RC
authors.lastname: Sheley
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon; D001132:Arm / Q000098:blood supply; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001367:Axillary Vein / Q000473:pathology; D016121:Brachiocephalic Veins / Q000473:pathology; D002408:Catheters, Indwelling / Q000009:adverse effects; D003251:Constriction, Pathologic / Q000628:therapy; D004868:Equipment Failure; D005260:Female; D006801:Humans; D007084:Iliac Vein / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011138:Polytetrafluoroethylene; D011446:Prospective Studies; D012008:Recurrence; D006435:Renal Dialysis; D012501:Saphenous Vein / Q000473:pathology; D015607:Stents; D013350:Subclavian Vein / Q000473:pathology; D016019:Survival Analysis; D014652:Vascular Diseases / Q000628:therapy; D014654:Vascular Patency; D014680:Veins / Q000473:pathology
chemical_list: D011138:Polytetrafluoroethylene